obj groundhog day - tell me it isn't so!, page-17

I would not mind to waste a few bottles of red in a year's time when we look back on 2 license agreements !

Yes, marketing staff at Ermington says that it needs to stay competitive with a changing market and that production would be placed overseas.
Ermington staff would concentrate on what they do best,
producing pain relief medicines.

Wonder when we will hear from GSK any news regarding pain relief research of our patch technologies.
Some of us clearly expect GSK not only being interested in the FIM technology applications but see this as the tip of the iceberg and a pharmaceutical application to be followed.
This would explain the many years GSK has been involved with us.